Smith & Nephew Meets on the Top Line, Misses Where it Counts
Smith & Nephew (NYS: SNN) reported earnings on May 2. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 30 (Q1), Smith & Nephew met expectations on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue was unchanged. Non-GAAP earnings per share dropped. GAAP earnings per share dropped.
Gross margins grew, operating margins dropped, net margins contracted.
Smith & Nephew logged revenue of $1.08 billion. The six analysts polled by S&P Capital IQ predicted sales of $1.07 billion on the same basis. GAAP reported sales were the same as the prior-year quarter's.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.92. The four earnings estimates compiled by S&P Capital IQ anticipated $0.95 per share. Non-GAAP EPS of $0.92 for Q1 were 2.1% lower than the prior-year quarter's $0.94 per share. GAAP EPS of $0.16 for Q1 were 11% lower than the prior-year quarter's $0.18 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 75.0%, 10 basis points better than the prior-year quarter. Operating margin was 19.3%, 260 basis points worse than the prior-year quarter. Net margin was 13.3%, 160 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $1.09 billion. On the bottom line, the average EPS estimate is $0.96.
Next year's average estimate for revenue is $4.39 billion. The average EPS estimate is $3.78.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 112 members out of 122 rating the stock outperform, and 10 members rating it underperform. Among 32 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 29 give Smith & Nephew a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Smith & Nephew is hold, with an average price target of $57.56.
Is Smith & Nephew the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Smith & Nephew to My Watchlist.
The article Smith & Nephew Meets on the Top Line, Misses Where it Counts originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.